VK2735's mid-stage results were strong; few drugmakers have posted phase 2 results of this caliber. Viking is developing VK2735 in both subcutaneous and oral formulations, and is exploring different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results